GB201904373D0 - Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Info

Publication number
GB201904373D0
GB201904373D0 GBGB1904373.6A GB201904373A GB201904373D0 GB 201904373 D0 GB201904373 D0 GB 201904373D0 GB 201904373 A GB201904373 A GB 201904373A GB 201904373 D0 GB201904373 D0 GB 201904373D0
Authority
GB
United Kingdom
Prior art keywords
treatment
novel compounds
inflammatory disorders
pharamaceutical compositions
pharamaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1904373.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GBGB1904373.6A priority Critical patent/GB201904373D0/en
Publication of GB201904373D0 publication Critical patent/GB201904373D0/en
Priority to BR112021019055A priority patent/BR112021019055A2/pt
Priority to AU2020252038A priority patent/AU2020252038A1/en
Priority to PCT/EP2020/058064 priority patent/WO2020200900A1/en
Priority to JP2021557761A priority patent/JP2022526364A/ja
Priority to MX2021011576A priority patent/MX2021011576A/es
Priority to PH1/2021/552375A priority patent/PH12021552375A1/en
Priority to US17/599,465 priority patent/US20220218679A1/en
Priority to EP20715295.0A priority patent/EP3947378B1/en
Priority to CA3134736A priority patent/CA3134736A1/en
Priority to CN202080025098.XA priority patent/CN113646305A/zh
Priority to SG11202110644WA priority patent/SG11202110644WA/en
Priority to MA055497A priority patent/MA55497A/fr
Priority to KR1020217035254A priority patent/KR20210145238A/ko
Priority to TW109110404A priority patent/TW202102501A/zh
Priority to ARP200100870A priority patent/AR118521A1/es
Priority to IL286677A priority patent/IL286677A/en
Priority to CONC2021/0014223A priority patent/CO2021014223A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1904373.6A 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders Ceased GB201904373D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
KR1020217035254A KR20210145238A (ko) 2019-03-29 2020-03-24 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
EP20715295.0A EP3947378B1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN202080025098.XA CN113646305A (zh) 2019-03-29 2020-03-24 用于治疗炎性障碍的新化合物及其药物组合物
PCT/EP2020/058064 WO2020200900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2021557761A JP2022526364A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物
MX2021011576A MX2021011576A (es) 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
PH1/2021/552375A PH12021552375A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US17/599,465 US20220218679A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112021019055A BR112021019055A2 (pt) 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
CA3134736A CA3134736A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2020252038A AU2020252038A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SG11202110644WA SG11202110644WA (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA055497A MA55497A (fr) 2019-03-29 2020-03-24 Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
ARP200100870A AR118521A1 (es) 2019-03-29 2020-03-27 Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
TW109110404A TW202102501A (zh) 2019-03-29 2020-03-27 用於發炎疾病之治療之新穎化合物及其醫藥組合物
IL286677A IL286677A (en) 2019-03-29 2021-09-26 New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
CONC2021/0014223A CO2021014223A2 (es) 2019-03-29 2021-10-25 Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
GB201904373D0 true GB201904373D0 (en) 2019-05-15

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1904373.6A Ceased GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (18)

Country Link
US (1) US20220218679A1 (https=)
EP (1) EP3947378B1 (https=)
JP (1) JP2022526364A (https=)
KR (1) KR20210145238A (https=)
CN (1) CN113646305A (https=)
AR (1) AR118521A1 (https=)
AU (1) AU2020252038A1 (https=)
BR (1) BR112021019055A2 (https=)
CA (1) CA3134736A1 (https=)
CO (1) CO2021014223A2 (https=)
GB (1) GB201904373D0 (https=)
IL (1) IL286677A (https=)
MA (1) MA55497A (https=)
MX (1) MX2021011576A (https=)
PH (1) PH12021552375A1 (https=)
SG (1) SG11202110644WA (https=)
TW (1) TW202102501A (https=)
WO (1) WO2020200900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657242A4 (en) * 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine
JPWO2005108399A1 (ja) * 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN109890829B (zh) * 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3947378B1 (en) 2024-11-13
MX2021011576A (es) 2021-10-13
CN113646305A (zh) 2021-11-12
SG11202110644WA (en) 2021-10-28
TW202102501A (zh) 2021-01-16
CO2021014223A2 (es) 2021-11-19
CA3134736A1 (en) 2020-10-08
IL286677A (en) 2021-10-31
MA55497A (fr) 2022-02-09
WO2020200900A1 (en) 2020-10-08
JP2022526364A (ja) 2022-05-24
EP3947378A1 (en) 2022-02-09
US20220218679A1 (en) 2022-07-14
AR118521A1 (es) 2021-10-20
PH12021552375A1 (en) 2022-09-19
AU2020252038A1 (en) 2021-11-25
BR112021019055A2 (pt) 2021-11-30
KR20210145238A (ko) 2021-12-01

Similar Documents

Publication Publication Date Title
IL292690A (en) mrgprx2 antagonists for the treatment of inflammatory disorders
IL304526A (en) Production of compounds and preparations to inhibit the activity of shp2
GB201904373D0 (en) Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
SG11202107325TA (en) Methods and compositions for the treatment of fabry disease
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
SG11202104053TA (en) Compositions and methods for the treatment of estrogen-dependent disorders
IL289687A (en) Preparations for the treatment of hair loss
IL279634A (en) Preparations and methods for the treatment and prevention of neurological disorders
IL286685A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
ZA202006591B (en) Compositions for the treatment of hypertension
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
PL4069278T3 (pl) Sposoby i kompozycje do zapobiegania cukrzycy typu 1
HK40068361A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40068861A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40068360A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3585768A4 (en) SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE PROPHYLAXIS AND / OR TREATMENT OF AUTOIMMUNE, INFLAMMATORY, OR INFECTIOUS DISEASES
GB201807222D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders
HK40075926A (en) Compositions and methods for the treatment of estrogen-dependent disorders
GB201905536D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of metabolic disorders
GB202001421D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB202001420D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)